Probes, Inhibitors, and PROTACs (PIP) Core
Probes, Inhibitors, and PROTACs (PIP) Core
批准号:
10714240
负责人:
Amarnath Natarajan
金额:
$18.58万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-03-16 至 2028-06-30
关键词:
AddressAdrenal GlandsAlkynesAllelesAmino Acid SequenceBindingBinding SitesBiologicalBiologyBiotinBiotinylationCDK4 geneCDK5 geneCellsCenters of Research ExcellenceChemicalsChemistryColorectal CancerCommunitiesComplexCoupledDNA SequenceDNA lesionDataDevelopmentDrug TargetingDrug resistanceEnvironmentEvaluationExcisionExperimental GeneticsFDA approvedFaculty RecruitmentFundingFutureGeneticGenetic CodeGlycolysisGrantKineticsLegal patentLibrariesLysineMapsMass Spectrum AnalysisMethodsMissionModificationMolecularMolecular TargetMutateNebraskaNeurologicNucleic AcidsOrganoidsPathway AnalysisPhosphorylationPhosphotransferasesPost-Translational Protein ProcessingProtacProtein AnalysisProteinsProteomeProteomicsPublicationsRNA SequencesRecombinant ProteinsRegulationResearchResearch PersonnelResearch Project GrantsRoleScientistServicesSignal PathwaySignal TransductionSignaling MoleculeSiteStructureStructure-Activity RelationshipSystemT-LymphocyteTechnologyTherapeuticTimeTissuesUbiquitinUniversitiesValidationanalogassay developmentcancer biomarkerschemical geneticschemical synthesisdesigndifferential expressiondrug discoveryexperienceexperimental studyfunctional groupin vivoinhibitorinstrumentationinterestlead optimizationmedullary thyroid carcinomamembermulticatalytic endopeptidase complexneuroendocrine cancerneuropsychiatrynovelp53-binding protein 1pre-clinicalprogramsprotein degradationprotein functionprotein protein interactionrecruitresistance mechanismscaffoldscale upsmall moleculesmall molecule librariesspatiotemporaltherapeutic developmenttherapeutic targettooltreatment responseubiquitin-protein ligase
中文摘要
项目概述:探针,抑制剂和PROTACs (PIP)核心
英文摘要
Project Summary: Probes, Inhibitors, and PROTACs (PIP) Core
The overarching mission of the PIP Core is to use sophisticated chemistry and mass spectrometry for
development of small molecules that facilitate molecular target discovery and development. Genetic methods
are routinely used to identify, develop, and validate molecular targets. These methods rely on altering the DNA
or RNA sequences of the protein target. However, drug discovery relies on manipulating the function of the
corresponding proteins using small molecules. Often the results obtained through these complementary
strategies do not correlate.1 The incongruence associated with the results from these orthogonal approaches
can be attributed to the complex biology that is dependent on multiple functions i.e., enzymatic and scaffolding,
associated with the protein target. Modulating protein levels by altering the nucleic acids eliminates all the target
protein functions. However small molecule modulators can be tuned to induce either domain specific effects
(reversible or irreversible) or removal of the entire protein (PROTAC) with exquisite temporal control. These
could be tagged with photoactivatable or fluorescent molecules, or biotin to enable target identification and
validation, study mechanism of action, or characterize the associated interactome. In addition to the design and
synthesis of above types of small molecules, the PIP Core will also provide scale up services (mg to g) for
additional experiments such as in vivo validation of targets and hit-to-lead optimization studies to generate
structure activity relationship (SAR) data. Mass spectrometry will be used to characterize the impact of these
compounds on the proteome through quantitative analysis of proteins and posttranslational or chemical
modifications to validate mechanism of action and compensatory features that may contribute to drug resistance.
The Core will be led by Drs. Natarajan and Woods, who will bring complementary expertise to the PIP Core. Dr.
Natarajan has extensive expertise in developing probes, inhibitors, and PROTACs, using cutting edge chemistry
methods. Dr. Woods has extensive experience using mass spectrometry as a platform for delineating protein-
protein interactions, posttranslational modifications, and multivariate biomarkers of cancer response to therapy.
PIP Core services will be extensively utilized by CMTDD Research Project Leaders (RPLs), CMTDD members
and University researchers at large.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UPR Activators for Cancer Therapy
-
批准号:10357411
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2022
-
负责人:Amarnath Natarajan
-
依托单位:
UPR Activators for Cancer Therapy
-
批准号:10544342
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2022
-
负责人:Amarnath Natarajan
-
依托单位:
PROTACs for pancreatic cancer therapy
-
批准号:10027631
-
项目类别:
-
资助金额:$39.34万
-
财政年份:2020
-
负责人:Amarnath Natarajan
-
依托单位:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
-
批准号:10731443
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2016
-
负责人:Amarnath Natarajan
-
依托单位:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
-
批准号:9271163
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2016
-
负责人:Amarnath Natarajan
-
依托单位:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
-
批准号:9920109
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2016
-
负责人:Amarnath Natarajan
-
依托单位:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
-
批准号:9102393
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2016
-
负责人:Amarnath Natarajan
-
依托单位:
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer
-
批准号:8622788
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2014
-
负责人:Amarnath Natarajan
-
依托单位:
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer
-
批准号:8907404
-
项目类别:
-
资助金额:$3.09万
-
财政年份:2014
-
负责人:Amarnath Natarajan
-
依托单位:
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer
-
批准号:8777952
-
项目类别:
-
资助金额:$19.64万
-
财政年份:2014
-
负责人:Amarnath Natarajan
-
依托单位:
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
-
批准号:8117726
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2008
-
负责人:Amarnath Natarajan
-
依托单位:
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
-
批准号:8307000
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2008
-
负责人:Amarnath Natarajan
-
依托单位:
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
-
批准号:7684265
-
项目类别:
-
资助金额:$27.35万
-
财政年份:2008
-
负责人:Amarnath Natarajan
-
依托单位:
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
-
批准号:7380313
-
项目类别:
-
资助金额:$27.0万
-
财政年份:2008
-
负责人:Amarnath Natarajan
-
依托单位:
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
-
批准号:8138240
-
项目类别:
-
资助金额:$9.05万
-
财政年份:2008
-
负责人:Amarnath Natarajan
-
依托单位:
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
-
批准号:7924608
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2008
-
负责人:Amarnath Natarajan
-
依托单位:
HTS to Identify Small Molecule Inhibitors of Phospho-Specific Protein-Protein Int
-
批准号:7304180
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2007
-
负责人:Amarnath Natarajan
-
依托单位:
海外基金